Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer

Basit Öğe Kaydı
dc.contributor.authorOzaslan, Ersin
dc.contributor.authorTopaloglu, Ulas Serkan
dc.contributor.authorInanc, Mevlude
dc.contributor.authorErdem, Umut Gokmen
dc.contributor.authorDemir, Hacer
dc.contributor.authorArpaci, Erkan
dc.contributor.authorSeker, Mehmet Metin
dc.date.accessioned2024-02-23T14:49:05Z
dc.date.available2024-02-23T14:49:05Z
dc.date.issued2017
dc.departmentNEÜen_US
dc.description.abstractPurpose: To evaluate the efficacy and adverse events with cetuximab plus FOLFOX administered as second- and third-line therapy in metastatic colorectal cancer (mCRC) patients. Methods: IPatients were administered cetuximab plus FOLFOX as second- and third-line therapy from January 2010 through October 2015. mCRC patients with wild type KRAS were also given irinotecan and/or oxaliplatin combined with fluoropyrimidine +/- bevacizumab. Tumor response and survival were evaluated using RECIST and Kaplan-Meier method respectively. Results: Sixty patients were included this study. Cetuximab plus FOLFOX was administered to 40 (66.7%) patients as second-line and to 20 (33.3%) as third-line therapy. Themajority of the patients had a good ECOG performance status (PS) (0 or 1). Clinical benefit was partial plus stable disease and it was 75.0% for both of these two lines. The median progression free survival (PFS) was 7.1 months (95% CI=3.2-10.9) and 6.0 months (95% CI=2.4-9.6), in the second- and third-line (p=0.484). The median overall survival (OS) was 14.3 and 9.2 months in second- and third-line therapy respectively (p=0.071). The common toxicities were haematologic and gastrointestinal, mostly grade 1 and 2. Conclusion: The addition of cetuximab to FOLFOX was well-tolerated and had antitumor activity both in second and third-line therapy in patients with mCRC.en_US
dc.identifier.endpage868en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue4en_US
dc.identifier.pmid29155512en_US
dc.identifier.scopus2-s2.0-85045577395en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage863en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12452/17971
dc.identifier.volume22en_US
dc.identifier.wosWOS:000412789500007en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.ispartofJournal Of Buonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCetuximaben_US
dc.subjectChemotherapyen_US
dc.subjectColorectal Canceren_US
dc.subjectSecond Lineen_US
dc.subjectThird Lineen_US
dc.titleEfficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu